Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

DiaMedica Therapeutics (DMAC) Shares Outstanding (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Shares Outstanding readings, the most recent being $53.9 million for Q1 2026.

  • Quarterly Shares Outstanding rose 25.72% to $53.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $53.9 million through Mar 2026, up 25.72% year-over-year, with the annual reading at $53.7 million for FY2025, 25.51% up from the prior year.
  • Shares Outstanding hit $53.9 million in Q1 2026 for DiaMedica Therapeutics, roughly flat from $53.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $53.9 million in Q1 2026 and bottomed at $26.4 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $38.7 million, with a median of $38.0 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding changed 0.0% in 2022 before it surged 43.55% in 2023.
  • DiaMedica Therapeutics' Shares Outstanding stood at $26.4 million in 2022, then skyrocketed by 43.55% to $38.0 million in 2023, then grew by 12.81% to $42.8 million in 2024, then rose by 25.51% to $53.7 million in 2025, then increased by 0.26% to $53.9 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Shares Outstanding are $53.9 million (Q1 2026), $53.7 million (Q4 2025), and $52.1 million (Q3 2025).